| pubmed-article:17119917 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17119917 | lifeskim:mentions | umls-concept:C1418778 | lld:lifeskim |
| pubmed-article:17119917 | lifeskim:mentions | umls-concept:C0311404 | lld:lifeskim |
| pubmed-article:17119917 | lifeskim:mentions | umls-concept:C1159709 | lld:lifeskim |
| pubmed-article:17119917 | lifeskim:mentions | umls-concept:C1704735 | lld:lifeskim |
| pubmed-article:17119917 | lifeskim:mentions | umls-concept:C1516240 | lld:lifeskim |
| pubmed-article:17119917 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:17119917 | pubmed:dateCreated | 2006-12-29 | lld:pubmed |
| pubmed-article:17119917 | pubmed:abstractText | Synthetic agonists of peroxisome proliferator-activated receptor (PPAR)-delta have shown a promising pharmacological profile in preclinical models of metabolic and cardiovascular disease. At present, the pharmaceutical development of these drugs exploits the potential to raise plasma HDL-cholesterol in animals and their insulin-sensitising and glucose-lowering properties. PPAR-delta agonists have also proven to be powerful research tools that have provided insights into the role of fatty acid metabolism in human physiology and disease. Activation of PPAR-delta induces the expression of genes important for cellular fatty acid combustion and an associated increase in whole-body lipid dissipation. The predominant target tissue in this regard is skeletal muscle, in which PPAR-delta activation regulates the oxidative capacity of the mitochondrial apparatus, switches fuel preference from glucose to fatty acids, and reduces triacylglycerol storage. These changes counter the characteristic derangements of insulin- resistant skeletal muscle but resemble the metabolic adaptation to regular physical exercise. Apart from effects on fuel turnover, there is evidence for direct antiatherogenic properties, because PPAR-delta activation increases cholesterol export and represses inflammatory gene expression in macrophages and atherosclerotic lesions. Whereas conclusions about the full potential of PPAR-delta as a drug target await the result of large scale clinical testing, ongoing investigation of this nuclear receptor has greatly improved our knowledge of the physiological regulation of whole-body fuel turnover and the interdependence of mitochondrial function and insulin sensitivity. | lld:pubmed |
| pubmed-article:17119917 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17119917 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17119917 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17119917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17119917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17119917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17119917 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17119917 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:17119917 | pubmed:issn | 0012-186X | lld:pubmed |
| pubmed-article:17119917 | pubmed:author | pubmed-author:FürnsinnCC | lld:pubmed |
| pubmed-article:17119917 | pubmed:author | pubmed-author:WillsonT MTM | lld:pubmed |
| pubmed-article:17119917 | pubmed:author | pubmed-author:BrunmairBB | lld:pubmed |
| pubmed-article:17119917 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17119917 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:17119917 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17119917 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17119917 | pubmed:pagination | 8-17 | lld:pubmed |
| pubmed-article:17119917 | pubmed:meshHeading | pubmed-meshheading:17119917... | lld:pubmed |
| pubmed-article:17119917 | pubmed:meshHeading | pubmed-meshheading:17119917... | lld:pubmed |
| pubmed-article:17119917 | pubmed:meshHeading | pubmed-meshheading:17119917... | lld:pubmed |
| pubmed-article:17119917 | pubmed:meshHeading | pubmed-meshheading:17119917... | lld:pubmed |
| pubmed-article:17119917 | pubmed:meshHeading | pubmed-meshheading:17119917... | lld:pubmed |
| pubmed-article:17119917 | pubmed:meshHeading | pubmed-meshheading:17119917... | lld:pubmed |
| pubmed-article:17119917 | pubmed:meshHeading | pubmed-meshheading:17119917... | lld:pubmed |
| pubmed-article:17119917 | pubmed:meshHeading | pubmed-meshheading:17119917... | lld:pubmed |
| pubmed-article:17119917 | pubmed:meshHeading | pubmed-meshheading:17119917... | lld:pubmed |
| pubmed-article:17119917 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17119917 | pubmed:articleTitle | Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. | lld:pubmed |
| pubmed-article:17119917 | pubmed:affiliation | Department of Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria. clemens.fuernsinn@meduniwien.ac.at. | lld:pubmed |
| pubmed-article:17119917 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17119917 | pubmed:publicationType | Review | lld:pubmed |
| entrez-gene:5467 | entrezgene:pubmed | pubmed-article:17119917 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17119917 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17119917 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17119917 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17119917 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17119917 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17119917 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17119917 | lld:pubmed |
